JP2023542964A5 - - Google Patents
Info
- Publication number
- JP2023542964A5 JP2023542964A5 JP2023518498A JP2023518498A JP2023542964A5 JP 2023542964 A5 JP2023542964 A5 JP 2023542964A5 JP 2023518498 A JP2023518498 A JP 2023518498A JP 2023518498 A JP2023518498 A JP 2023518498A JP 2023542964 A5 JP2023542964 A5 JP 2023542964A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- hydrogen
- linear
- chain alkyl
- triazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200122540 | 2020-09-22 | ||
| KR10-2020-0122540 | 2020-09-22 | ||
| PCT/KR2021/012823 WO2022065831A1 (ko) | 2020-09-22 | 2021-09-17 | 그렐린 수용체 작용제로서의 트리아졸 화합물의 용도 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542964A JP2023542964A (ja) | 2023-10-12 |
| JP2023542964A5 true JP2023542964A5 (https=) | 2024-08-15 |
| JP7799262B2 JP7799262B2 (ja) | 2026-01-15 |
Family
ID=80845629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518498A Active JP7799262B2 (ja) | 2020-09-22 | 2021-09-17 | グレリン受容体作用剤としてのトリアゾール化合物の用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12570617B2 (https=) |
| EP (1) | EP4218757A4 (https=) |
| JP (1) | JP7799262B2 (https=) |
| KR (1) | KR102752714B1 (https=) |
| CN (2) | CN116669575B (https=) |
| WO (1) | WO2022065831A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022448086B2 (en) * | 2022-03-23 | 2024-02-01 | Nextgen Bioscience Co., Ltd. | Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for s1pr1 and s1pr4 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| ES2388501T3 (es) * | 2004-08-12 | 2012-10-16 | Helsinn Healthcare S.A. | Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal |
| US10975070B2 (en) * | 2010-02-26 | 2021-04-13 | Raqualia Pharma Inc. | Ghrelin receptor agonist for treatment of cachexia |
| EP2431035A1 (en) * | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
| KR20150020602A (ko) * | 2012-05-25 | 2015-02-26 | 라퀄리아 파마 인코포레이티드 | 무산증 치료를 위한 그렐린 수용체 효능물질 |
| ES2864079T3 (es) * | 2014-05-30 | 2021-10-13 | Pfizer | Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos |
| WO2017075535A1 (en) * | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| KR101830244B1 (ko) * | 2016-01-20 | 2018-02-21 | 서울대학교 산학협력단 | 신규한 헤테로방향족 고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 s1p 수용체 관련 질환의 예방 또는 치료용 약학적 조성물 |
| KR20180036318A (ko) | 2016-09-30 | 2018-04-09 | 경북대학교 산학협력단 | 2-아미노-2-(1-도데실-1h-1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체를 유효성분으로 포함하는 퇴행성 신경질환 및 우울증 예방 또는 치료용 약학적 조성물 |
| KR102292989B1 (ko) | 2017-03-29 | 2021-08-26 | 재단법인 아산사회복지재단 | S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물 |
| KR102017324B1 (ko) | 2018-04-30 | 2019-09-02 | 경북대학교 산학협력단 | 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도 |
| KR102609693B1 (ko) | 2019-04-18 | 2023-12-05 | 현대모비스 주식회사 | 차량의 전원 백업 장치 |
-
2021
- 2021-09-17 US US18/027,829 patent/US12570617B2/en active Active
- 2021-09-17 CN CN202180076726.1A patent/CN116669575B/zh active Active
- 2021-09-17 WO PCT/KR2021/012823 patent/WO2022065831A1/ko not_active Ceased
- 2021-09-17 JP JP2023518498A patent/JP7799262B2/ja active Active
- 2021-09-17 EP EP21872859.0A patent/EP4218757A4/en active Pending
- 2021-09-17 CN CN202510489733.4A patent/CN120081796A/zh active Pending
- 2021-09-17 KR KR1020210125105A patent/KR102752714B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021105030A (ja) | ニコチンアミドリボシドの結晶形 | |
| JP2023530084A5 (https=) | ||
| AU2014351486C1 (en) | Crystalline forms of lesinurad and its sodium salt | |
| EP1988898A2 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
| JP2017510624A5 (https=) | ||
| US11667630B2 (en) | Nitrogen-containing 6-membered cyclic compound | |
| RS66885B1 (sr) | Соли или кокристали 3-(3-диметиламино-1-етил-2-метил-пропил)-фенола | |
| JP2009538309A5 (https=) | ||
| JP2011527675A5 (https=) | ||
| US20160101179A1 (en) | Compound formulations of 2-amino-1, 3-propanediol compounds | |
| JP2023542964A5 (https=) | ||
| WO2021187548A1 (ja) | 慢性心不全の治療又は予防方法 | |
| TW201139421A (en) | Novel ep4 agonist | |
| JP2021503451A5 (https=) | ||
| JP2021519797A (ja) | 腎傷害を治療するための組成物および方法 | |
| BG65472B1 (bg) | Използване на саредутант и неговите фармацевтичноприемливи соли за приготвяне на лекарствено средство за използване за лечение или профилактика на голямо депресивно разтройство | |
| JP2022516989A5 (https=) | ||
| EP1257552B1 (fr) | Derives de xanthine, intermediaires et application au traitement de l'osteoporose | |
| US20080234323A1 (en) | Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride | |
| ES2203889T3 (es) | Tratamiento de infecciones protozoarias. | |
| RU2005105688A (ru) | Полиморфизм додекагидроциклопента (а) фенантренилового эфира тиофенкарбоновой кислоты | |
| US12048689B2 (en) | Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4 | |
| JPH08511008A (ja) | 複素環式化学 | |
| WO2020249117A1 (zh) | 抗高血压的多元醇化合物及其衍生物 | |
| JP5960695B2 (ja) | パンテニルドコサヘキサエノアート、ならびに心血管疾患を治療および予防するためのその使用 |